Christopher T Ritchlin1, Mona Stahle2, Yves Poulin3, Jerry Bagel4, Soumya D Chakravarty5,6, Shelly Kafka5, Bhaskar Srivastava5, Wayne Langholff7, Alice B Gottlieb8. 1. 1Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, 601 Elmwood Ave., Box 695, Rochester, NY 14642 USA. 2. Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. 3. 3Université Laval and Centre de Recherche Dermatologique du Quebec métropolitain, Quebec, Canada. 4. 4Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ USA. 5. 5Janssen Scientific Affairs, LLC, Horsham, PA USA. 6. 6Drexel University College of Medicine, Philadelphia, PA USA. 7. 7Janssen Research & Development, Spring House, PA USA. 8. 8New York Medical College, Metropolitan Hospital, New York, NY USA.
Abstract
BACKGROUND: Patients with psoriatic arthritis (PsA) have increased risk of adverse events, including serious infections (SI), compared with psoriasis patients. METHODS: Patients eligible for, or receiving conventional systemic and biologic agents for psoriasis were followed prospectively using PSOLAR. Cohorts included: ustekinumab, tumor necrosis factor (TNF) inhibitors; infliximab; etanercept; adalimumab; non-biologic/methotrexate (MTX) (reference group); and non-biologic/non-MTX. Multivariate analyses using Cox hazard regression were used to identify factors associated with time to first SI. Rates of SI in PSOLAR psoriasis patients with self-reported PsA and possible risks with biologic therapy were evaluated. RESULTS: PSOLAR enrolled 4315 psoriasis patients with self-reported PsA. The overall population (N = 2401) included patients (n): 628 ustekinumab; 1413 TNF inhibitors; 258 infliximab; 481 etanercept; 674 adalimumab; 54 other biologics, 98 non-biologic/MTX; 208 non-biologic/non-MTX. Overall, 138 SI were reported with incidence rates per 100 patient-years as follows: a) ustekinumab: 1.00; b) TNF inhibitors: 2.22; c) infliximab: 2.12; d) etanercept: 2.58; e) adalimumab: 1.99; f) non-biologic/MTX: 3.01; g) and non-biologic/non-MTX: 2.31. Age, time-dependent disease activity Physician's Global Assessment (PGA) of 4, 5, history of infection, and diabetes were associated with increased risk for SI (p < 0.05) in self-reported PsA patients. Biologic groups, other than ustekinumab, had numerically higher rates of SI. CONCLUSIONS: PSOLAR psoriasis patients with self-reported PsA in the TNF inhibitors, infliximab, adalimumab, etanercept, and MTX cohorts had numerically higher SI rates than the ustekinumab cohort, although not statistically significant. Age, PGA 4, 5, history of infection, and diabetes were associated with an increased risk for SI, irrespective of biologic exposure. TRIAL REGISTRATION: NCT00508547; Registered July 30, 2007.
BACKGROUND: Patients with psoriatic arthritis (PsA) have increased risk of adverse events, including serious infections (SI), compared with psoriasis patients. METHODS: Patients eligible for, or receiving conventional systemic and biologic agents for psoriasis were followed prospectively using PSOLAR. Cohorts included: ustekinumab, tumor necrosis factor (TNF) inhibitors; infliximab; etanercept; adalimumab; non-biologic/methotrexate (MTX) (reference group); and non-biologic/non-MTX. Multivariate analyses using Cox hazard regression were used to identify factors associated with time to first SI. Rates of SI in PSOLAR psoriasis patients with self-reported PsA and possible risks with biologic therapy were evaluated. RESULTS: PSOLAR enrolled 4315 psoriasis patients with self-reported PsA. The overall population (N = 2401) included patients (n): 628 ustekinumab; 1413 TNF inhibitors; 258 infliximab; 481 etanercept; 674 adalimumab; 54 other biologics, 98 non-biologic/MTX; 208 non-biologic/non-MTX. Overall, 138 SI were reported with incidence rates per 100 patient-years as follows: a) ustekinumab: 1.00; b) TNF inhibitors: 2.22; c) infliximab: 2.12; d) etanercept: 2.58; e) adalimumab: 1.99; f) non-biologic/MTX: 3.01; g) and non-biologic/non-MTX: 2.31. Age, time-dependent disease activity Physician's Global Assessment (PGA) of 4, 5, history of infection, and diabetes were associated with increased risk for SI (p < 0.05) in self-reported PsA patients. Biologic groups, other than ustekinumab, had numerically higher rates of SI. CONCLUSIONS: PSOLAR psoriasis patients with self-reported PsA in the TNF inhibitors, infliximab, adalimumab, etanercept, and MTX cohorts had numerically higher SI rates than the ustekinumab cohort, although not statistically significant. Age, PGA 4, 5, history of infection, and diabetes were associated with an increased risk for SI, irrespective of biologic exposure. TRIAL REGISTRATION: NCT00508547; Registered July 30, 2007.
Authors: Sofia Ramiro; Cécile Gaujoux-Viala; Jackie L Nam; Josef S Smolen; Maya Buch; Laure Gossec; Désirée van der Heijde; Kevin Winthrop; Robert Landewé Journal: Ann Rheum Dis Date: 2014-01-08 Impact factor: 19.103
Authors: Erica D Dommasch; Katrina Abuabara; Daniel B Shin; Josephine Nguyen; Andrea B Troxel; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2011-02-18 Impact factor: 11.527
Authors: Robert E Kalb; David F Fiorentino; Mark G Lebwohl; John Toole; Yves Poulin; Arnon D Cohen; Kavitha Goyal; Steven Fakharzadeh; Stephen Calabro; Marc Chevrier; Wayne Langholff; Yin You; Craig L Leonardi Journal: JAMA Dermatol Date: 2015-09 Impact factor: 10.282
Authors: Peter Nash; Bruce Kirkham; Masato Okada; Proton Rahman; Benard Combe; Gerd-Ruediger Burmester; David H Adams; Lisa Kerr; Chin Lee; Catherine L Shuler; Mark Genovese Journal: Lancet Date: 2017-05-24 Impact factor: 79.321
Authors: Paula Dávila-Seijo; Esteban Dauden; M A Descalzo; Gregorio Carretero; José-Manuel Carrascosa; Francisco Vanaclocha; Francisco-José Gómez-García; Pablo De la Cueva-Dobao; Enrique Herrera-Ceballos; Isabel Belinchón; José-Luis López-Estebaranz; Merce Alsina; José-Luis Sánchez-Carazo; Marta Ferrán; Rosa Torrado; Carlos Ferrandiz; Raquel Rivera; Mar Llamas; Rafael Jiménez-Puya; Ignacio García-Doval Journal: J Invest Dermatol Date: 2016-09-25 Impact factor: 8.551
Authors: Kim A Papp; Bruce Strober; Matthias Augustin; Steve Calabro; Anil Londhe; Marc Chevrier Journal: J Drugs Dermatol Date: 2012-10 Impact factor: 2.114
Authors: Philip J Mease; Désirée van der Heijde; Christopher T Ritchlin; Masato Okada; Raquel S Cuchacovich; Catherine L Shuler; Chen-Yen Lin; Daniel K Braun; Chin H Lee; Dafna D Gladman Journal: Ann Rheum Dis Date: 2016-08-23 Impact factor: 19.103
Authors: A Richter; J Listing; M Schneider; T Klopsch; A Kapelle; J Kaufmann; A Zink; A Strangfeld Journal: Ann Rheum Dis Date: 2015-11-13 Impact factor: 19.103
Authors: Michael J Peluso; Jessica Chen; Sadie Munter; Asia Reed; Justin Teraoka; Ingrid Eshun-Wilson; Timothy J Henrich; Peter V Chin-Hong Journal: AIDS Date: 2020-07-01 Impact factor: 4.177